Celgene slips on ozanimod speculation

Amid a broad decline in biotech indexes Monday, Celgene Corp. (NASDAQ:CELG) dropped $4.08 (4%) to $87.10 as speculation around the timeline for multiple sclerosis candidate ozanimod heats up ahead of

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE